215 related articles for article (PubMed ID: 32642735)
1. NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation.
Lobón-Iglesias MJ; Laurendeau I; Guerrini-Rousseau L; Tauziède-Espariat A; Briand-Suleau A; Varlet P; Vidaud D; Vidaud M; Brugieres L; Grill J; Pasmant E
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i98-i106. PubMed ID: 32642735
[TBL] [Abstract][Full Text] [Related]
2. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.
Chen Y; Yu J; Ge S; Jia R; Song X; Wang Y; Fan X
Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):8. PubMed ID: 38837168
[TBL] [Abstract][Full Text] [Related]
5. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
[TBL] [Abstract][Full Text] [Related]
6. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
7. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
Chang L; El-Dairi MA; Frempong TA; Burner EL; Bhatti MT; Young TL; Leigh F
J AAPOS; 2010 Dec; 14(6):511-7. PubMed ID: 21168074
[TBL] [Abstract][Full Text] [Related]
8. Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications.
Shamji MF; Benoit BG
Neurosurg Focus; 2007; 23(5):E3. PubMed ID: 18004965
[TBL] [Abstract][Full Text] [Related]
9. Optic pathway glioma and endocrine disorders in patients with and without NF1.
Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S
Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247
[TBL] [Abstract][Full Text] [Related]
10. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
[TBL] [Abstract][Full Text] [Related]
12. Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care.
Miyagishima KJ; Qiao F; Stasheff SF; Nadal-Nicolás FM
Vision (Basel); 2024 May; 8(2):. PubMed ID: 38804352
[TBL] [Abstract][Full Text] [Related]
13. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
14. NF1 mutation drives neuronal activity-dependent initiation of optic glioma.
Pan Y; Hysinger JD; Barron T; Schindler NF; Cobb O; Guo X; Yalçın B; Anastasaki C; Mulinyawe SB; Ponnuswami A; Scheaffer S; Ma Y; Chang KC; Xia X; Toonen JA; Lennon JJ; Gibson EM; Huguenard JR; Liau LM; Goldberg JL; Monje M; Gutmann DH
Nature; 2021 Jun; 594(7862):277-282. PubMed ID: 34040258
[TBL] [Abstract][Full Text] [Related]
15. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
16. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas.
Johnson KJ; Fisher MJ; Listernick RL; North KN; Schorry EK; Viskochil D; Weinstein M; Rubin JB; Gutmann DH
Fam Cancer; 2012 Dec; 11(4):653-6. PubMed ID: 22829012
[TBL] [Abstract][Full Text] [Related]
17. Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience.
Del Baldo G; Cacchione A; Dell'Anna VA; Merli P; Colafati GS; Marrazzo A; Rossi S; Giovannoni I; Barresi S; Deodati A; Valente P; Ferretti E; Capece M; Mastronuzzi A; Carai A
Front Surg; 2022; 9():890875. PubMed ID: 35784925
[TBL] [Abstract][Full Text] [Related]
18. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
[TBL] [Abstract][Full Text] [Related]
19. Measurements of Retinal Nerve Fiber Thickness and Ganglion Cell Complex in Neurofibromatosis Type 1, with and Without Optic Pathway Gliomas: A Case Series.
Sahinoglu-Keskek N; Altan-Yaycioglu R; Canan H; Coban-Karatas M; Erbay A; Yazıcı N; Alkan O
Curr Eye Res; 2018 Mar; 43(3):424-427. PubMed ID: 29185816
[TBL] [Abstract][Full Text] [Related]
20. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
